ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Therapeutic Drug Carrier Systems
インパクトファクター: 2.9 5年インパクトファクター: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN 印刷: 0743-4863
ISSN オンライン: 2162-660X

巻:
巻 38, 2021 巻 37, 2020 巻 36, 2019 巻 35, 2018 巻 34, 2017 巻 33, 2016 巻 32, 2015 巻 31, 2014 巻 30, 2013 巻 29, 2012 巻 28, 2011 巻 27, 2010 巻 26, 2009 巻 25, 2008 巻 24, 2007 巻 23, 2006 巻 22, 2005 巻 21, 2004 巻 20, 2003 巻 19, 2002 巻 18, 2001 巻 17, 2000 巻 16, 1999 巻 15, 1998 巻 14, 1997 巻 13, 1996 巻 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2018025649
pages 137-181

Long-Acting Injectables: Current Perspectives and Future Promise

Komal Chaudhary
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
Mayur M. Patel
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
Priti J. Mehta
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India

要約

The parenteral route of administration is preferred over the oral route for treatment of many chronic and life-threatening diseases due to better patient compliance. Long-acting injectables/depot delivery systems are formulations intended for prolonged/sustained drug release over a long period of time ranging from a few days to months. Depot delivery systems enhance product quality by decreasing dosing frequency, simplifying the drug regimen. Parenteral depots reduce the relapse rate of disease and the maintenance phase of therapy, hence improving efficacy and treatment adherence. However, despite being extensively explored in the last seventy years, only a few depot products have been marketed or have reached commercial viability. The introduction of long-acting injectables of any drug took 9 to 10 years after approval of its oral formulation. Mainly the market has been conquered by long-acting injectables for antipsychotic, substance abuse, and hormonal therapy drugs.
This article focuses on the preparation of long-acting injectables with special emphasis on challenges associated with formulation. The evolution and current global market trend of various depot formulations are also discussed. Insight is provided into the promising future of long-acting injectables of protein-based drugs as well as multidrug therapy, along with potential uses in the treatment of chronic diseases like HIV, Parkinson's, and Alzheimer's.


Articles with similar content:

Rationalized Insights on Causes of Rheumatoid Arthritis in the Elderly and Women: Special Emphasis on Treatment Strategies
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 2
Shikha Srivastava, Deependra Singh, Satish Patel, Manju Rawat Singh
Endothelial Cells as Therapeutic Targets in Cancer: New Biology and Novel Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 2&3
J. C. Murray, S. Moein Moghimi
Inflammatory Bowel Disease: Pathogenesis, Causative Factors, Issues, Drug Treatment Strategies, and Delivery Approaches
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 3
Shikha Srivastava, Madhulika Pradhan, Deependra Singh, Manju Rawat Singh, Jagat R. Kanwar
Critical Aspects in Rationale Design of Fluorouracil-Based Adjuvant Therapies for the Management of Colon Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 2
Vivek Ranjan Sinha, Honey
Conundrum and Therapeutic Potential of Curcumin in Drug Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.27, 2010, issue 4
Javed Ali, Sanjula Baboota, Anil Kumar, Alka Ahuja